Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.
Keywords: Neuroendocrine tumors; angiogenesis inhibitors; biomarkers; cytotoxic chemotherapy; liver-targeted therapies; radionuclide therapy; somatostatin analogs.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.